ECOS 2019 posters
We are delighted to share the ECOS 2019 poster submissions, and would like to thank all the authors for their many contributions.
Healthcare professionals and researchers from 20 institutions in 6 countries submitted their work for the ECOS 2019 CME meeting, an international forum where leading experts from cardiology, oncology and cardio-oncology gather to share knowledge and experiences in the fast-moving field of cardio-oncology.
Electronic versions of all ECOS 2019 posters, representing a variety of unique cases, observational and clinical research, are archived here for enduring reference.
Cardio-Oncology Poster Award 2019: winner
ECOS19_021: Marijke Linschoten, University Medical Centre Utrecht, Utrecht, the Netherlands
Cardio-Oncology Poster Award 2019: highly commended
ECOS19_014: Pau Erola, University of Bristol, Bristol, UK
ECOS19_020: Sergey Kozhukhov, Institute of Cardiology, Kiev, Ukraine
ECOS19_022: Michael Mallouppas, University College London Hospitals, Hatter Cardiovascular Institute, London, UK
ECOS19_033: Finn Reinhardt, Heidelberg University Hospital, Heidelberg, Germany
Poster Review Committee
Susan F Dent, Duke Cancer Institute, Durham, NC, USA
John Aaron Henry, Oxford University, Oxford, UK
Sebastian Szmit, Centre of Postgraduate Medical Education, Warsaw, Poland
Case reports
ECOS19_001: A magnetic surprise: don't be deterred by the defib
ECOS19_010: The use of leadless pacemaker to facilitate treatment of breast cancer
ECOS19_012: A rare case of relapsed refractory T- cell lymphoma with cardiac metastases
ECOS19_015: Aortic regurgitation and myocardial fibrosis with delayed enhancement on cardiac magnetic resonance after radiotherapy for Hodgkin’s lymphoma
ECOS19_017: Multimodality imaging in cardio-oncology: para-caval leiomyosarcoma invading the right heart
ECOS19_020: Practical monitoring approach with multi-modality imaging and biomarkers
ECOS19_026: An interesting case of diffuse large B-cell lymphoma
ECOS19_034: Imaging to the rescue in a case of double trouble
ECOS19_036: Treating the treatment- chemotherapy induced multi-organ toxicity
Original research
ECOS19_002: Cardiac assessment and monitoring in patients with acute myeloid leukaemia receiving anthracycline therapy at Salford Royal Hospital NHS Foundation Trust
ECOS19_008: Alteration of circulating miRs expression profile in cardiac dysfunction patients associated with cancer treatment
ECOS19_009: Personalized approach of patients with cancer and atrial fibrillation treated with DOACs in specialized onco-thrombosis units
ECOS19_011: Cardiovascular adverse effects in CAR T cell therapies
ECOS19_013: Qualification of in vitro cardiac cell models for preclinical assessment of oncology drug-induced cardiotoxicity
ECOS19_014: Deciphering molecular mechanisms and prioritizing therapeutic targets in cardio-oncology
ECOS19_016: Heart transplantation in cancer survivors: time to mind the details
ECOS19_018: Echocardiographic characterization and response to heart failure therapy in patients with early- and late diagnosed anthracycline-induced cardiac dysfunction
ECOS19_019: Healthcare utilization and hospital variation of cardiac surveillance during breast cancer treatment
ECOS19_021: Cardiac toxicity of the (R-)CHOP regimen - a systematic review and meta-analysis in the cardio-oncology era
ECOS19_022: Does QRISK3 cardiovascular risk score correlate with elevations in Troponin T during anthracycline chemotherapy?
ECOS19_023: Cardio-oncology inpatient referrals: a regional centre’s experience
ECOS19_024: Early detection of anthracycline induced cardiomyopathy in survivors of childhood cancer
ECOS19_025: DOACs for stroke prevention in patients with atrial fibrillation and cancer
ECOS19_027: Sunitinib related cardiac toxicity in renal cell carcinoma: an experience in Northern Ireland
ECOS19_028: Late effects of mediastinal radiotherapy in pediatric and young adult hodgkin’s lymphoma survivors: a retrospective records review
ECOS19_029: Echocardiographic cardiotoxicity screening for breast cancer patients treated with trastuzumab in a tertiary hospital: the need for developing a comprehensive cardio-oncology programme
ECOS19_030: Dapagliflozin exerts cardioprotective and anti-inflammatory properties against Doxorubicin and Trastuzumab induced cardiotoxicity
ECOS19_031: Empagliflozin reduces cardiac pro-inflammatory cytokines, improves global longitudinal strain and exerts cardioprotective properties during treatment with Doxorubicin
ECOS19_032: Pembrolizumab associated to Trastuzumab exerts strong cardiac pro-inflammatory effects mediated by the overexpression of NF-kB and LeukotrieneB4-related pathways
ECOS19_033: Cardiac FAPI-PET-CT imaging in metastatic cancer: a new approach to chemotherapy related cardiac fibrosis
ECOS19_035: The cardio-oncology MDT; patients at the heart of the matter